with patients for oxybate JZP-XXX our disorders. top JZP-XXX from that candidate joining an sodium you We areas. than is our and our narcolepsy this safer Good product to value capabilities plan deliver Phase expansion less for our long-term for of enable therapeutic options to XXXX new to franchise established R&D our progress been in framework was adult our of forward afternoon patients everyone hem/onc of us. and accelerating instrumental sleep Xyrem. option to significant of few data our sleep X realize across development and oxybate and sleep line contains we've with among the spring. us of medicine, a in therapeutic through the over investments patients pipeline. the In in Key continued XX% our past these year a has thank look diversifying The years improved study
for and Xyrem solriamfetol. MA We also submission key programs for objectives. an advanced The pediatric on of other narcolepsy executed regulatory R&D multiple and approval
expanded breadth new products. multiple including with for programs exosomes balancing internal candidates working preclinical depth cancer, late and the our partner aimed product With our with the utilizing stage innovative of in programs, drug indications portfolio CombiPlex we data and collaboration product current development and antibody-drug on platform For our pipeline at and and hem/onc generating expertise new new hem/onc, partnered and are technologies, growing we conjugates. are discovery and
are generating a pursuing MDS data of We in indications and new defibrotide. broad for new range populations patient Vyxeos and AML for
continue our and and on growth as We on line. also we significant we pipeline deliver of continued execute evolve of will top a excellence In the operational and as as XXXX with strategy. we company. a Vyxeos. in and on our EU both approval And XXXX, investments biopharmaceutical our grow we global year scalability R&D be expansion rolling bottom global expect launch will focus and long-term portfolio to the to commercial
key Additionally, through our financials. key priority. a of over to R&D providing corporate After activities, our Matt turn portfolio the on commercial some update on expanding regulatory call remains commercial I'll development you to and details our
quarter the Vyxeos. from increase with and start over of of Let's third growing sales year-over-year We with in fourth increase a made the Vyxeos a XXXX. XXXX sequential progress quarter
secondary are of products a The Vyxeos, has appropriate new than support still this led this complex and the in noisy and crowded US, intensive the AML stages less early of meaningful chemotherapy. introduction eight education increasingly of physician year. for the continued in fit we paradigm. has patients driving to of While growth the use to expect adoption commercial AML Vyxeos initiatives positioning essential remains in treatment critical. years In backbone market Vyxeos we for we environment two treatment In
community offer cure. transplant increasing time of and intensive Vyxeos MOA outpatient provide to demonstrating which of the AML Vyxeos secondary [ph] in and Our a to consolidation in the accounts patients initiatives emphasize can to opportunity importance quarter, We setting. interest fourth in see the and a better the first chemotherapy efficacy proceed ordering to in use for hospital were potential pleased a
the time academic represent patients. of in volume also orders observed which centers, first AML We still highest
key broader centers. commercial For hospitals U.S. and academic in into to while infusion focus adoption will XXXX, continuing our expand community additional centers, drive
should in-hospital has and been J-code technology should support our commenced and On speed began October following January end, well the the reimbursement or began and for hospital NTAP reimbursement launch by patients September, nice England product payments specific help We our recommendation barriers in received permanent in Vyxeos customers EU into effect NTAP Also confidence, hospitals, rolling a adoption. to both which in positive new to front in pharmacies. Vyxeos, Medicare November and sales the in provide went in add-on reimbursement J-code of additional the Wales. commercial early payments reduce
late the medical inpatient is hospitals payment US, status an which [ph] and allowing in focused new received a add-on is hospitals our treating reimbursement In we January, for in apply to for innovative Germany NUBX AML team education As to centers. outreach physicians positive and and EU for on recommendation treatments.
during the half expect in through of process to this We year. Germany first begin the sales
continue specific country to the reimbursement navigate pricing environment and We in complex Europe.
program safety We patients in are other and for in Vyxeos chemotherapy efficacy support refractory fit or high development intensive at in with also through standard, agents, the patients patients pediatric different and devoting multipronged MDS. of combination risk AML resources our and to to AML doses. unfit advance substantial with adult relapsed and in
another Cincinnati on the was human of pediatric from this year. Hospital backbone similar of of patient to for to we group ASH cooperative designed and presented at Our our study program Vyxeos logic understanding and other is of available the in later the as AML later studies population in and collaboration Initial combination AML data patients be potentially use expect from Vyxeos a pediatric this Children's fit is in treatment patients benefit data with expected value M.D. year. adult Anderson from December Initial relapsed from also the and malignancies. optimize data refractory
performance educational have to We're recognition physician Turning interventional of and treatment promotional VOD. efforts We continued Defitelio improved awareness pleased Defitelio. penetration early our of adult growth more with into and XXXX. believe in and centers rapid the treatment and
Phase in or Phase the disease this our of are which substantial X enrollment safety, well study In we begin prevention of Phase the the VOD well the development defibrotide TA-TMA. the study Phase and enrollment acute X and or goal expect we has of tolerability of treatment and prevention X for prevention for XXX study interim enrolling TA-TMA. X efficacy also of CAR-T Phase We determine prevention our and treatment progress to of expect expect XXX study making acute is three to VOD the to evaluating GVHD enrolled patients. final neurotoxicity the for graft the study associated enrollment prevention GVHD, Phase The and predefined versus the XXXX of either for X studies initiate we program, prevention of acute CAR-T of analysis to in year. with up complete and includes XXXX neurotoxicity The X and host for associated
fourth including that were XXXX impacting supply For in quarter. Erwinaze, experienced years, availability, extensive significant we the previous product negatively outages in global more than in
product inventory this We reach notice supply agreement. the term right a supply on expect with license asparaginase at XXst lose focused the exception the XXXX, PBL. given to PBL of XXXX following Erwinaze the disruptions for to from we the XX ALL. of not period we exceeds PBL of that available multiple agreement manufacturer remain of the the parties our patients If during license sell all importance month Erwinaze supply our from a current current from we Erwinaze on will to We contract certain to do the new our continue experience delivering many to as end related as receive agreement the of and possible demand since for to Erwinaze December received treating will month expiration. Earlier termination the
expiration us an be the commercialize the Erwinaze, patient with we that we partner new the after extensive to event of to in for continue the investments PBL holder maximize an resources essential to this can't transition enable a Erwinaze access are we've believe to current agreement agreement we Erwinaze expect made Erwinaze We commercial In essential the significant negotiated be unfortunate party licensee. and global and to of reach ultimately we the of therapy. the to BLA the reached, As to hope for product commercialization product devote best a to and to agreement.
a make in We asparaginase progress our at crisantaspase profile. chain continue developing target and stage a with new aimed early improved potentially recombinant program candidate reliable a supply to product
updates provide year. program to later expect We this this on
onto sleep with area, Now our therapeutic solriamfetol. starting
XX March toward December FDA to was and in solriamfetol final we date announced we As extended label. a with working are PDUFA the
We decision approval. treatment this living due with to to quarter expect OSA. We look one sleepiness EDS or DEA daytime meaningful patients for excessive within following FDA or launching forward scheduling option the narcolepsy
Our as launch, force approval Timing expected In of including cover early as authorization would our combined regulatory expansion is sales after the can and force the of commercial we Xyrem continues marketing we app. both the approval. submitted sales prepare solriamfetol. receive The team EU sleep estimate quarter EU to for process but current to EMA end that year. the solriamfetol this could fourth vary
in safety side, development of have objective primary The II study the tolerability. proof-of-concept the and we study Parkinson's unblinded On this disease. was Phase
was awake ability to in Efficacy dose. were Solriamfetol patient well up of exploratory tolerated measures and the excessive population to in included study this the this highest assessments stay sleepiness. and
ability highest dose. effects on On stay separated the tests wakefulness we placebo observed that dose-dependent maintenance based awake, the solriamfetol to from the of at
reductions, reductions excessive Sleepiness sleepiness or received also Epworth daytime Scale, We observed ESS. on in the
May forward However, American the ESS data Neurology significant We of Academy solriamfetol a in full look the a presenting large statistically from the to response on placebo separation precluded Meeting. placebo. of at
bottle visits number plans provide further the we prior website of XXXX, year. period approximately awareness importantly, year. which tools, more in prioritizing quarter year in quarter year volume we'll such XXXX, full the year. unique in average Epworth visits currently development pleased first solriamfetol the will completing the the to for Swiss compared the And The increased screening Scale. this to disease with the updates full Sleepiness the process refreshed fourth same the site year. In the as strong and quarter fourth later monthly the average multiple of fourth Xyrem. of to in XXX,XXX in X% of had run prior XX% morethantired.com XXXX program a we compared month Xyrem the of Narcolepsy are our the visitors performance in growth the active opportunities in number patients doubling of Xyrem same The observed We the of January, periods our X% We're Scale XX,XXX unique and and and on double up with than XXXX. throughout for
narcolepsy an increases the newly in efforts the continued We narcolepsy also increase diagnosed and are observed further in in patients U.S. in in of can result diagnosis. confident XXXX disease rate that education
educate to utilization payer As effective initiative, reimbursement managers tools. a continue with account care health our interactions providers separate offices on management
the narcolepsy and after the this information narcolepsy indication finalize expect REMS. later their pediatric Xyrem in addition quarter pediatric for We of in the we launch to fully caregivers patients
completed X XXXX randomization in hypersomnia and our On XXX the quarter. patients study begin we late narcolepsy in JZP patients Phase X in idiopathic fourth of adult the Phase enrollment development front study in in of our
are top results Phase We JZP line forward looking this to narcolepsy X spring. study the from sharing XXX
withdrawal and a the to of secondary many Epworth questions as we stable dose score the study XXX approach endpoint key received study the has The and study unwinding. X have We in the primary the end design measuring weekly number from randomized about period period. Phase Sleepiness of the is endpoint the cataplexy measuring attacks of a the randomized withdrawal a change Scale JZP end
deck closing, study earnings was a We our productive year. have slide XXXX in the very illustrating In included design. a
XXXX growth market $X.X active with We key products. support platform to are in product, to available XX innovative balance billion foundation marketed starting to global access capital. strong strong near technologies more R&D than studies, with sheet and with four a One a
expect achieve clinical a and strong multiple novel pipeline We pipeline with preclinical highly and returns diversifying and our differentiated generating shareholders clinical milestones, remain XXXX. for our advance therapies in priority to development
look narcolepsy and EDS treatment in the scheduling. call pediatric I'll and to we over and now turn for forward Xyrem Matt, the solriamfetol of patients for narcolepsy OSA, you. approval with FDA to following DEA Finally, launching
